(ERAS) Erasca, Inc. Porters Five Forces Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ERAS) Erasca, Inc. Complete Analysis Pack
Elevate Your Analysis with the Complete Porter's Five Forces Analysis
This Erasca, Inc. Porter's Five Forces Analysis helps you understand the company’s competitive environment, including rivalry, buyer power, supplier power, substitutes, and new entrants. The page already shows a real preview of the actual report, so you can review the content before buying. Purchase the full version for the complete ready-to-use analysis.
Suppliers Bargaining Power
Specialized biotech inputs
Supplier leverage is high for Erasca, Inc. because its work depends on specialized CROs, CDMOs, assay vendors, and preclinical labs with few qualified substitutes. In biotech, switching a technical partner can delay studies and raise burn rate, so even small price hikes can matter. This makes Erasca’s supplier base a real bottleneck in trial timing and cost control.
Manufacturing capacity dependence
Erasca, Inc. has no internal commercial-scale plant, so it depends on outside CMOs for drug substance and drug product. In 2025, tight biologics and small-molecule slots still let suppliers control price and batch timing, especially for Phase 2 and Phase 3 supply. That dependence can raise trial risk if capacity shifts or release timelines slip.
Clinical trial materials
Supplier power is high for Erasca because clinical trial materials depend on a small group of GxP-compliant vendors for patient kits, cold-chain shipping, and blinded labeling. Switching suppliers can trigger revalidation, requalification, and protocol delays, which makes these vendors sticky and limits Erasca’s flexibility. In 2025, that risk is sharper as clinical trial supply chains remain tightly regulated and capacity is still concentrated.
Regulatory-grade quality standards
Supplier power is high for Erasca because GMP and GLP-qualified vendors are scarce, so the company cannot just switch to cheaper suppliers without risking compliance breaches. In oncology R&D, even one supplier quality failure can halt studies, trigger rework, and add months of delay. That raises cost and keeps critical vendors in a strong bargaining position.
- Few GMP/GLP-ready suppliers
- Low-cost switching is risky
- Failures can delay trials
- Remediation adds cost and time
Talent and scientific expertise
Scientific talent is a strong supplier in Erasca, Inc.'s oncology work because skilled drug developers, clinical operators, and niche consultants are scarce and can choose among many biotech employers. That tight labor market gives them pricing and negotiating power, especially in Phase 1-3 cancer trials where speed and trial quality matter most. In 2025, biotech hiring stayed highly competitive, so the same experts often sit across multiple programs at once.
- Scarce oncology expertise raises supplier power.
- Competition for talent lifts pay and terms.
- Specialists can move across biotech firms.
Erasca’s Supplier Dependence Could Slow Trials and Raise Costs
Erasca, Inc. faces high supplier power because it relies on a narrow set of CROs, CDMOs, assay labs, and GMP/GLP vendors, and switching them can delay trials and raise costs. With no internal commercial-scale plant, outside CMO capacity and batch timing can shape Phase 2 and Phase 3 supply. Scarce oncology talent also strengthens vendor leverage in 2025.
| Driver | Impact |
|---|---|
| Specialized vendors | High |
| Switching risk | Revalidation delays |
| Internal manufacturing | None |
What is included in the product
Detailed Word Document
Analyzes Erasca, Inc.’s competitive pressures, supplier and buyer power, and threats from entrants and substitutes.
Customizable Excel Spreadsheet
A quick, board-ready view of Erasca’s competitive pressure—making biotech strategy decisions faster and easier.
Reference Sources
Provides a clear source trail for Erasca, Inc., making the analysis more credible and easier to use in decisions.
Customers Bargaining Power
Patients do not directly pay
Erasca’s patients usually do not pay the bill directly; insurers, hospitals, and government programs do, so the real buyer is the payer. In the U.S., about 92% of people had health insurance in 2025, which pushes adoption toward reimbursement reviews, not retail demand.
That lowers direct customer concentration, but it raises gatekeeper power because coverage decisions can make or break use. For a clinical-stage company like Erasca, approval and payer support matter more than patient price sensitivity.
So Erasca must prove clear clinical value and a strong cost case to win coverage.
Payers control access
Payers control access, and that gives them leverage over Erasca, Inc.’s oncology pricing. In 2025, health insurers and national systems still demanded proof of overall survival or meaningful quality-of-life gains before backing premium drug prices, so even approved drugs can face steep discounts, step edits, or restricted coverage. That cuts Erasca’s pricing power and can delay broad uptake.
Physician prescribing power
Oncologists heavily shape Erasca, Inc.’s customer power because they rely on NCCN/ESMO guidance, biomarker fit, and real-world outcomes before switching therapy. In solid tumors, many treatment decisions hinge on whether a drug beats standard care on efficacy and tolerability, so if Erasca’s assets do not show clear clinical edge, physicians will stay with established options. With U.S. cancer deaths still near 600,000 a year, even small gains in response or safety can shift prescribing.
Small number of large buyers
Once Erasca, Inc. commercializes, a small group of large hospital systems, specialty pharmacies, and payers could control most volume. In FY2025, Erasca still had no product revenue, so future buyers will likely push hard on discounts, prior auth, and formulary access. That concentration can squeeze net pricing fast.
- Few buyers, high leverage.
- Prior auth can block demand.
- Formulary placement drives volume.
Trial sites and partners
In 2025, Erasca still had no commercial revenue, so trial sites and investigators were key gatekeepers for patient enrollment and study speed. The U.S. has 72 NCI-designated cancer centers, and top oncology sites often pick among many sponsors, which gives them real pricing and priority power.
That matters because scarce sites can steer patients to better-funded trials, slow enrollment, or demand stronger site support. For Erasca, this raises operating risk and can push up trial costs, especially in competitive oncology programs.
- 72 NCI-designated cancer centers in the U.S.
- No 2025 product revenue at Erasca
- Enrollment speed depends on site priority
Erasca Faces Strong Buyer Power as Payers Control Access
Erasca, Inc. faces strong buyer power because payers, not patients, decide access. In FY2025, Erasca, Inc. had no product revenue, so any future pricing will depend on payer coverage and clinician uptake, not retail demand. Large payers and hospital systems can press for rebates, prior auth, and narrow formularies.
| Item | Data |
|---|---|
| FY2025 product revenue | 0 |
| U.S. insured rate, 2025 | 92% |
| U.S. NCI cancer centers | 72 |
Same Document Delivered
Erasca, Inc. Porter's Five Forces Analysis
This preview shows the exact Erasca, Inc. Porter’s Five Forces Analysis you’ll receive after purchase—no samples, no placeholders, no surprises. The same professionally written document is ready for immediate download, covering the full competitive landscape in a clear, practical format. What you see here is the final version, so you can buy with confidence knowing the delivered file will match this preview exactly.
Rivalry Among Competitors
Crowded oncology pipeline
Oncology is a crowded field, and RAS/MAPK is especially packed: by 2025, 4 KRAS-targeted drugs were already approved, with many more in trials.
Erasca competes not only with large pharma, but also with mid-cap biotech and venture-backed startups chasing precision oncology and targeted therapy wins.
That raises rivalry because even small clinical data reads can shift funding, partnering, and valuation fast.
Mechanism overlap risk
ERK, SHP2, and EGFR are crowded targets, with many firms advancing similar drugs, so Erasca, Inc. faces real mechanism overlap risk. In 2025, multiple late-stage EGFR and SHP2 programs were still active across large pharma and biotech, which raises the odds of near-simultaneous launches. If rivals reach market together, pricing power and differentiation can narrow fast.
Late-stage data competition
In biotech, late-stage data beats scale: one strong Phase 2/3 readout can reset partner interest and valuation overnight. A rival with better efficacy, cleaner safety, or sharper biomarker selection can quickly overshadow Erasca. The first credible readout often sets the market story.
Big pharma advantage
Big pharma has a clear edge here: large oncology players spend billions on R&D and can fund late-stage trials, combo studies, and fast sales rollouts at a scale Erasca cannot match. Their broad oncology field teams and long payer ties also help them win access faster if they enter Erasca's target spaces.
- Outspend on trials and combos
- Use wider oncology sales reach
- Leverage payer relationships
- ضغط pricing and market access
Partnering and licensing pressure
Biotech rivalry for Erasca, Inc. is not just about trial data; it is also about locking up licenses, co-development rights, and buyout targets. Big peers can move faster on scarce biomarker platforms and partner assets, so Erasca must prove capital markets credibility and execution speed to avoid being shut out of the best deals.
- Deal speed is a competitive edge.
- Scarce assets get taken first.
- Execution risk rises if funding slips.
- Partner credibility now matters as much as science.
In oncology, partnering can decide who controls the next 1-to-3 year catalyst path, not just the pipeline.
Erasca Faces Fierce Oncology Competition
Competitive rivalry is high for Erasca, Inc. because 4 KRAS-targeted drugs were approved by 2025, while ERK, SHP2, and EGFR still had many active rivals in late-stage development. In oncology, one Phase 2/3 readout can reset value fast, so better efficacy, safety, or biomarker fit can quickly displace Erasca. Big pharma also raises pressure with deeper R&D budgets, broader sales reach, and stronger payer ties.
| 2025 signal | Why it matters |
|---|---|
| 4 KRAS approvals | Crowded target space |
| Many SHP2/ERK/EGFR trials | Overlap risk is high |
| Late-stage readouts | Data can shift valuation fast |
Substitutes Threaten
Standard-of-care therapies
Standard chemotherapy, immunotherapy, and targeted regimens remain the main substitutes for Erasca’s pipeline. Keytruda alone generated $29.5 billion in 2024 sales, showing how entrenched incumbent standards are. Even when a new therapy looks better on paper, physicians often stay with familiar regimens that already have reimbursement support, so substitution risk stays meaningful.
Other pathway inhibitors
Other pathway inhibitors raise Erasca, Inc.'s substitute risk because drugs aimed at upstream or adjacent targets can bypass RAS/MAPK dependence. If those therapies deliver longer survival or work in broader patient groups, they can draw demand away from Erasca's assets, especially in biomarker-defined tumors. The threat rises as more targeted options move into late-stage trials and approved use.
Combination regimens
Combination regimens are a real substitute threat for Erasca, Inc. because they can beat single-agent or dual-target therapy on response and resistance control. In EGFR-mutant NSCLC, osimertinib plus chemotherapy and amivantamab-based combinations have raised the bar, while the FDA approved 80+ oncology drugs in 2025, showing how fast combo standards can shift. If a competitor’s mix delivers deeper, longer control, Erasca’s monotherapy thesis weakens.
Non-drug interventions
For Erasca, Inc., non-drug substitutes are real in localized cancer care: surgery, radiation, and watchful waiting can replace systemic therapy when tumors are early stage or slow growing. The threat is not broad; it depends on indication, because advanced metastatic disease usually still needs drug treatment. In the U.S., about 2.0 million new cancer cases are expected in 2025, but many early-stage cases still start with local control.
That means substitute pressure is highest in resectable or radiation-sensitive tumors, and lower in late-line settings where Erasca, Inc. targets unmet need. One clean rule: stage drives substitution risk.
- Highest threat: localized, operable tumors
- Lower threat: advanced metastatic disease
- Key driver: stage and tumor type
Off-label and repurposed drugs
Off-label and repurposed drugs can blunt Erasca, Inc.'s uptake when physicians can use older, cheaper options first. In lung cancer, erlotinib and osimertinib are already approved, so any Erasca program must show clear, durable benefit; a small PFS edge often won’t shift prescribing. This threat is highest when the new therapy is incremental, not clearly better on response or survival.
- Lower cost can slow switching.
- Familiar drugs reduce first-line risk.
- Big efficacy gaps matter most.
High Substitute Risk Pressures Erasca’s Pipeline
Threat of substitutes for Erasca, Inc. is high because standard chemo, immunotherapy, targeted drugs, and even surgery or radiation can replace its pipeline in many settings. In 2024, Keytruda alone did $29.5 billion in sales, showing how hard it is to displace entrenched standards. Substitution risk is highest in early-stage or biomarker-adjacent cancers, and lower in late-line metastatic disease.
| Substitute | Signal | Impact |
|---|---|---|
| Keytruda | $29.5B 2024 sales | High |
Entrants Threaten
High capital requirements
Drug discovery, translational work, and oncology trials need huge upfront capital; a single new drug can cost over $1 billion to develop, and Phase 3 oncology studies often run into tens or hundreds of millions. For Erasca, Inc., that means a new entrant must fund years of R&D before any product revenue appears. This cash burn creates a far stronger barrier than in most industries.
Regulatory complexity
Regulatory complexity is a major barrier for new biopharma entrants. To reach market, they must clear IND filings, clinical protocols, GMP checks, and FDA NDA/BLA review, and drug R&D still fails often: only about 10% of candidates enter human testing and reach approval.
That slows cash use and raises risk, while FDA approved just 50 novel drugs in 2024.
For Erasca, Inc., this friction makes rapid new entry less likely.
Scientific know-how barrier
Target selection, biomarker strategy, and trial design need deep precision-oncology expertise, and weak science can end a startup fast. Erasca reported $248.8 million in cash, cash equivalents, and marketable securities at March 31, 2026, but capital alone does not buy credibility. New entrants without seasoned teams still face a high bar to build programs that survive early scrutiny.
IP and patent defenses
Erasca, Inc. and peers can use patents, know-how, and data exclusivity to fence off their lead programs. In the U.S., patents can last 20 years from filing, while small-molecule drugs can get 5 years of FDA data exclusivity and biologics 12 years, so new entrants must design around claims or risk infringement. That raises cost, time, and legal risk in the same niche.
- Patents create direct blocking rights
- Exclusivity delays fast follow-on entry
- Know-how is harder to copy
- Design-around work adds R&D cost
Access to patients and partners
Access to patients and partners is a real barrier for Erasca, Inc. Clinical trial enrollment, academic collaborators, and manufacturing slots are scarce, so new biotech firms often wait months to build site networks and vendor access. Established relationships with cancer centers and CROs favor incumbents, which lowers the threat of new entrants.
- Limited trial sites slow new rivals
- Partner ties favor incumbents
- Vendor slots add long lead times
Erasca’s Entry Barriers Stay High
Threat of new entrants for Erasca, Inc. is low because oncology biotech needs heavy capital, long timelines, and deep trial expertise. A new drug can cost over $1 billion to develop, and only about 10% of candidates that enter human testing reach approval, making early failure costly.
IP also protects incumbents: patents can last 20 years from filing, while U.S. data exclusivity can reach 5 years for small molecules and 12 years for biologics. On top of that, Erasca had $248.8 million in cash, cash equivalents, and marketable securities at March 31, 2026, showing the scale newcomers must match.
| Barrier | Key data |
|---|---|
| R&D cost | >$1 billion per drug |
| Approval success | ~10% reach approval |
| Erasca liquidity | $248.8 million |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.